Screening For Prostate Cancer Treatment In Delhi

Screening For Prostate Cancer Treatment In Delhi

Prostate Cancer Treatment In Delhi: Prostate cancer is considered as the most common cancer in men and is a common cause of death in many individuals. However, screening with Prostate Specific Antigen(PSA) test can reduce the number of deaths from prostate cancer. This is slow-growing cancer and many men do not benefit from the treatment as this causes long term side effects with urinary and sexual dysfunction. Hence screening should be properly done as per specific guidelines for early detection and diagnosis of cancer so that treatment can be effectively taken to eradicate from the beginning.

Guidelines For Prostate Cancer Treatment In Delhi

The guidelines to screen prostate cancer have been issued by the following organizations:

      • American Cancer Society(ACS) guidelines

    According to the guidelines last updated in the year 2010, ACS generally not implies for any routine screening in the men of any age group. Healthcare provider should give clear information about the uncertainties, risks, and benefits of screening to men, even though don’t exhibit such symptoms and who can have 10 years of life expectancy. Men should be provided with information at the starting age such as,

        1. Age 50 – those who are at average risk of getting the cancer
        2. Age 45- Those at higher risk with one first-degree relative diagnosed with prostate cancer.
        3. Age 40- Those at higher risk with more than one first-degree relatives diagnosed with this cancer.

    Those men who are in a dilemma whether to be screened or not, our healthcare provider can make the decision of screening in you taking into account your general health, values or preferences. The screening process involves a PSA test and a

DRE(Digital Rectal Exam)

    • . If screening does not detect any cancer, the time between subsequent screenings depends on the results of the blood test, as follows:

      • PSA < 2.5 ng/ml – Retesting may be done every 2 years
      • PSA ≥ 2.5 ng/ml – Retesting should be done annually
    • National Comprehensive Cancer Network (NCCN) Guidelines

According to these guidelines, a baseline evaluation of an individual should be done with history and physical examination that includes the following:
      1. Family history
      2. Medications
      3. History of prostate disease and screening, including prior PSA and/or isoforms, exams, and biopsies
      4. Race
      5. Family or personal history of BRC1/2 mutations

The clinician should also discuss the risks and benefits of the baseline PSA test to the patient and recommend to go for baseline DRE to identify high-risk cancers associated with normal PSA. In patients 45-75 years of age, subsequent evaluation is based on the results of those tests, as follows:

      1. PSA < 1 ng/mL, DRE normal (if done): Repeat testing at 2–4 year intervals
      2. PSA 1-3 ng/mL, DRE normal (if done): Repeat testing at 1–2 year intervals
      3. PSA >3 ng/mL or very suspicious DRE result: Evaluate for biopsy
    • American Urological Association

These guidelines do not recommend routine screening for men under following age categories:

      • Any man with a life expectancy less than 10-15 years
      • Men under 40 years
      • Men between ages 40 to 54 years at average risk
      • Men over age 70

Men who fall under the age category of 55 to 69 years PSA screening is done depending on their shared decision making of men considering the balance between risks and benefits. Routine screening of two years or more can be recommended.

    • U.S. Preventive Services Task Force (USPSTF) These guidelines were updated in the year 2012, considering the patient’s own preferences and values. Individuals are asked to make their own decisions before which should never be ordered.
    • European Society for Medical Oncology (ESMO) These guidelines recommend against population-based PSA screening for prostate cancer, as well as a screening of asymptomatic men over 70 years old.
    • European Association of Urology/European Society for Radiotherapy and Oncology/International Society of Geriatric Oncology (EAU/ESTRO/SIOG)

According to these revised and joint guidelines, those men who are being informed and request for screening should be given a PSA test and to undergo a DRE. PSA testing should be offered to the following groups at elevated risk for developing prostate cancer

  • Men > age 50
  • Men > age 45 and a family history of prostate cancer
  • African-American men > age 45
  • Men with a PSA level of > 1 ng/mL at age 40
  • Men with a PSA level of > 2 ng/mL at age 60

Follow-up testing at intervals of 2 years for the following at-risk groups:

  • Men with a PSA level of > 1 ng/mL at age 40
  • Men with a PSA level of > 2 ng/mL at age 60
  • Postpone follow-up to 8 years in those not at risk.

Dr. Ashish Saini is one of the most experienced urologists who has the best Prostrate clinic in Delhi. He is an expert in treating patients who have kidney stones, renal colic, hydronephrosis, renal and prostate cancer, BPH(Benign Prostatic Hyperplasia) and male infertility problems. The doctor uses cutting-edge technology in diagnosing patient’s cancer thereby rendering appropriate Prostate cancer treatment in Delhi. For a permanent cure of your illness book an appointment with him online or visit his clinic.


Comments are closed.